By Dr Louise Emmett

Journal articles

Murphy DG; Emmett L, 2024, 'PSMA PET Staging is Advised for All High-Risk Patients With Localized Prostate Cancer', International Journal of Radiation Oncology Biology Physics, 120, pp. 642 - 645, http://dx.doi.org/10.1016/j.ijrobp.2024.06.031

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.', J Nucl Med, http://dx.doi.org/10.2967/jnumed.124.267606

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Trapp C; Aebersold DM; Belka C; Casuscelli J; Emmett L; Eze C; Fanti S; Farolfi A; Fendler W; Grosu AL; Guckenberger M; Hruby G; Kirste S; Koerber SA; Kroeze S; Peeken JC; Rogowski P; Scharl S; Shelan M; Spohn SKB; Strouthos I; Unterrainer L; Vogel M; Wiegel T; Zamboglou C; Schmidt-Hegemann NS, 2024, 'Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis', European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 3770 - 3781, http://dx.doi.org/10.1007/s00259-024-06802-x

Soon YY; Marschner IC; Schou M; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2024, 'Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer', JAMA network open, 7, pp. e2433863, http://dx.doi.org/10.1001/jamanetworkopen.2024.33863

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of ⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on ⁶⁸Ga-PSMA-11 PET/CT', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Emmett L; Papa N; Hope TA; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Counter W; John N; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Agrawal S; Ho B; Nguyen A; Liu V; Lee J; Woo H; Hsiao E; Sutherland T; Perry E; Stricker P; Hofman MS; Kasivisvanathan V; Roberts M; Murphy D, 2024, 'Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer', Journal of Urology, 212, pp. 299 - 307, http://dx.doi.org/10.1097/JU.0000000000004010

Menzies AM; Lo SN; Saw RPM; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee J; Emmett L; Kapoor R; Rawson RV; Stretch JR; Thompson JF; Spillane AJ; Rizos H; Scolyer RA; Long GV, 2024, 'Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma', Annals of Oncology, 35, pp. 739 - 746, http://dx.doi.org/10.1016/j.annonc.2024.05.002

Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM, 2024, 'Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals', PET Clinics, 19, pp. 371 - 388, http://dx.doi.org/10.1016/j.cpet.2024.03.003

Swiha M; Gafita A; Nguyen A; Emmett L, 2024, 'Treatment Response Imaging in Prostate Cancer', PET Clinics, 19, pp. 417 - 430, http://dx.doi.org/10.1016/j.cpet.2024.03.009

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to ¹⁷⁷Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Kwan EM; Hofman MS; Ng SWS; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Tolmeijer SH; Azad A; Davis ID; Wyatt AW, 2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', Journal of Clinical Oncology, 42, pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5055

Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L, 2024, 'Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [⁶⁸Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer', European urology oncology, 7, pp. 544 - 552, http://dx.doi.org/10.1016/j.euo.2023.11.008

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2024, 'European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy', Radiotherapy and Oncology, 194, http://dx.doi.org/10.1016/j.radonc.2024.110215

Gafita A; Martin AJ; Emmett L; Eiber M; Iravani A; Fendler WP; Buteau J; Sandhu S; Azad AA; Herrmann K; Stockler MR; Davis ID; Hofman MS, 2024, 'Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.', Eur Urol Oncol, http://dx.doi.org/10.1016/j.euo.2024.03.009

Geboers B; Meijer D; Counter W; Blazevski A; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; O'Neill G; Yuen C; Vis AN; van Leeuwen PJ; Ho B; Liu V; Lee J; Donswijk ML; Oprea-Lager D; Scheltema MJ; Emmett L; Stricker PD, 2024, 'Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy', BJU International, 133, pp. 14 - 22, http://dx.doi.org/10.1111/bju.16207

Geboers B; Scheltema MJV; Emmett L; Stricker PD, 2024, 'Reply to ‘Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy’', BJU International, 133, pp. 25 - 26, http://dx.doi.org/10.1111/bju.16308

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RDA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L, 2024, 'The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy', BJU International, 133, pp. 39 - 47, http://dx.doi.org/10.1111/bju.16158

Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M, 2024, 'A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET–Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study', JMIR Cancer, 10, http://dx.doi.org/10.2196/60323

Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S, 2024, 'European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer', European Urology, 85, pp. 49 - 60, http://dx.doi.org/10.1016/j.eururo.2023.09.003

Swiha M; Ayati N; Oprea-Lager DE; Ceci F; Emmett L, 2024, 'How to Report PSMA PET', Seminars in Nuclear Medicine, 54, pp. 14 - 29, http://dx.doi.org/10.1053/j.semnuclmed.2023.07.007

Sollini M; Calais J; Chiti A; Emmett L; Fanti S; Fendler W; Herrmann K; Hope TA; Sartor O; Shuch B; Tagawa S; Hofman MS, 2024, 'Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers', European Urology, http://dx.doi.org/10.1016/j.eururo.2024.09.036

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6

Roberts MJ; Papa N; Veerman H; de Bie K; Morton A; Franklin A; Raveenthiran S; Yaxley WJ; Donswijk ML; van der Poel HG; Samaratunga H; Wong D; Brown N; Parkinson R; Gianduzzo T; Kua B; Coughlin GD; Oprea-Lager DE; Emmett L; van Leeuwen PJ; Yaxley JW; Vis AN, 2024, 'Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics', BJU International, http://dx.doi.org/10.1111/bju.16482

Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA, 2024, 'Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database', Journal of Nuclear Medicine, 65, http://dx.doi.org/10.2967/jnumed.123.266164

Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M, 2024, 'The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 558 - 567, http://dx.doi.org/10.1007/s00259-023-06438-3

Trapp C; Aebersold DM; Belka C; Casuscelli J; Ceci F; Emmett L; Fanti S; Farolfi A; Grosu A-L; Guckenberger M; Henkenberens C; Hruby G; Koerber SA; Kroeze S; Peeken JC; Rogowski P; Scharl S; Shelan M; Spohn, SKB; Strouthos I; Unterrainer L; Vogel M; Wiegel T; Zamboglou, C; Schmidt-Hegemann N-S, 2024, '1443: Whole vs. hemi pelvis RT in patients with PSMA-positive nodal recurrence - a retrospective analysis', Radiotherapy and Oncology, 194, pp. S2436 - S2438, http://dx.doi.org/10.1016/s0167-8140(24)01834-6

Hofman MS; Gafita A; Bressel M; Alipour R; Levy S; Emmett L; Ravi Kumar AS; Hamid AA; Buteau JP; Kuo PH; Chen DL; Hope TA; Armstrong AJ; Scher HI; Schoder H; Sandhu SK; Morris MJ, 2024, '1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial', Annals of Oncology, 35, pp. S970 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1689

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Zamboglou C; Staus P; Wolkewitz M; Peeken JC; Vogel M; Ferentinos K; Strouthos I; Farolfi A; Koerber SA; Vrachimis A; Spohn SKB; Shelan M; Grosu A-L; Kroeze SGC; Hruby G; Morganti AG; Wiegel T; Emmett L; Fanti S; Guckenberger M; Hayoz S; Belka C; Aebersold DM; Schmidt-Hegemann N-S; Ghadjar P, 2024, '200: PSMA-PET/CT improves outcomes after salvage radiotherapy for recurrent prostate cancer after surgery', Radiotherapy and Oncology, 194, pp. S2297 - S2298, http://dx.doi.org/10.1016/s0167-8140(24)00904-6

Russell M; Emmett L; Peric B; Saw R; Spillane J; Vazquez V; Duprat J; Moncreiff M; Allan C; Leeuwen BV; Pritchard-Jones R; Rastrelli M; de Wilt H; Geh J; Howle J; Spillane A, 2024, 'Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial', European Journal of Surgical Oncology, 50, pp. 107397 - 107397, http://dx.doi.org/10.1016/j.ejso.2023.107397

Emmett L; Papa N; Hope T; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Liu V; Nguyen A; Hsiao E; Stricker P; Hofman M; Kasivisvanathan V; Roberts M; Murphy D, 2024, 'Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer', European Urology, 85, pp. S476 - S476, http://dx.doi.org/10.1016/s0302-2838(24)00417-2

Vis A; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van Der Ven PM; Heymans MW; Nieuwenhuijzen JA; Van Der Poel HG; Van Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes A-M; Oprea-Lager DE; Coughlin GD; Van Leeuwen PJ, 2024, 'Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission', European Urology, 85, pp. S483 - S484, http://dx.doi.org/10.1016/s0302-2838(24)00422-6

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua A; Emmett L; Murphy D; Hsiao E; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS, 2024, 'LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)', Annals of Oncology, 35, pp. S1255 - S1256, http://dx.doi.org/10.1016/j.annonc.2024.08.2309

Van Leeuwen PJ; Berrens A-C; Vis A; Yaxley J; Meijer D; Siriwardana A; Wit E; Van Der Noort V; Morton A; Franklin A; Yaxley J; Wong D; Goughlin G; Gianduzzo T; Kua B; Emmett L; Zuur L; Van Der Poel H; Roberts M, 2024, 'The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort study', European Urology, 85, pp. S1263 - S1264, http://dx.doi.org/10.1016/s0302-2838(24)01002-9

Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes AM; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ, 2023, 'Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography', European urology oncology, 6, pp. 553 - 563, http://dx.doi.org/10.1016/j.euo.2023.03.010

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne H; Tunariu N; Ho B; Young S; Singbo MNU; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial', Cancer Imaging, 23, http://dx.doi.org/10.1186/s40644-023-00570-x

Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G, 2023, 'Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer', Radiation Oncology, 18, http://dx.doi.org/10.1186/s13014-023-02302-8

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J, 2023, '⁶⁸Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study', Translational Andrology and Urology, 12, pp. 1598 - 1606, http://dx.doi.org/10.21037/tau-22-708

Pouliot F; Emmett L, 2023, 'Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now', European Urology, 84, pp. 371 - 372, http://dx.doi.org/10.1016/j.eururo.2023.07.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Roberts MJ; Hruby G; Kneebone A; Martin JM; Williams SG; Frydenberg M; Murphy DG; Namdarian B; Yaxley JW; Hofman MS; Davis ID; Emmett L, 2023, 'Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?', BJU International, 132, pp. 146 - 148, http://dx.doi.org/10.1111/bju.16086

Mei R; Kessler L; Pabst KM; Weber M; Schmidkonz C; Rischpler C; Zacho HD; Hope T; Schwarzenbock SM; Allen-Auerbach M; Emmett L; Ferdinandus J; Unterrainer M; Schaarschmidt BM; Umutlu L; Farolfi A; Castellucci P; Nanni C; Telo S; Fanti S; Herrmann K; Fendler WP, 2023, '⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study', Journal of Nuclear Medicine, 64, pp. 1043 - 1048, http://dx.doi.org/10.2967/jnumed.122.265245

Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D, 2023, 'A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy', European Urology Open Science, 53, pp. 90 - 97, http://dx.doi.org/10.1016/j.euros.2023.05.002

Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K, 2023, 'Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2830 - 2845, http://dx.doi.org/10.1007/s00259-023-06255-8

Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C, 2023, 'PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2529 - 2536, http://dx.doi.org/10.1007/s00259-023-06185-5

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2023, 'Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study', Radiotherapy and Oncology, 184, http://dx.doi.org/10.1016/j.radonc.2023.109678

Back to profile page